Publication | Closed Access

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

Breast OncologyLba1 TrastuzumabMedicineImmunologyPathologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentVs Trastuzumab EmtansineOncologyRadiation OncologyTumor Biology